News
To overcome these limitations, Antengene developed ATG-201, a “2+1” CD19 x CD3 TCE, which was evaluated in a series of in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback